BOSTON SCIENTIFIC CORP (BSX.DE) Fundamental Analysis & Valuation

FRA:BSX • US1011371077

Current stock price

60.2 EUR
-1.2 (-1.95%)
Last:

This BSX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BSX.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BSX was profitable.
  • BSX had a positive operating cash flow in the past year.
  • BSX had positive earnings in each of the past 5 years.
  • Each year in the past 5 years BSX had a positive operating cash flow.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • BSX has a Return On Assets of 6.64%. This is in the better half of the industry: BSX outperforms 75.81% of its industry peers.
  • With a decent Return On Equity value of 11.96%, BSX is doing good in the industry, outperforming 75.81% of the companies in the same industry.
  • BSX has a better Return On Invested Capital (8.70%) than 69.35% of its industry peers.
  • BSX had an Average Return On Invested Capital over the past 3 years of 7.70%. This is below the industry average of 10.01%.
  • The 3 year average ROIC (7.70%) for BSX is below the current ROIC(8.70%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROIC 8.7%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.44%, BSX belongs to the top of the industry, outperforming 85.48% of the companies in the same industry.
  • BSX's Profit Margin has improved in the last couple of years.
  • BSX's Operating Margin of 19.92% is amongst the best of the industry. BSX outperforms 82.26% of its industry peers.
  • BSX's Operating Margin has improved in the last couple of years.
  • BSX has a Gross Margin of 69.01%. This is amongst the best in the industry. BSX outperforms 80.65% of its industry peers.
  • In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
Industry RankSector Rank
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BSX.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
  • BSX has more shares outstanding than it did 1 year ago.
  • BSX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BSX has an improved debt to assets ratio.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 4.28 indicates that BSX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.28, BSX is in the better half of the industry, outperforming 75.81% of the companies in the same industry.
  • BSX has a debt to FCF ratio of 3.13. This is a good value and a sign of high solvency as BSX would need 3.13 years to pay back of all of its debts.
  • BSX's Debt to FCF ratio of 3.13 is fine compared to the rest of the industry. BSX outperforms 74.19% of its industry peers.
  • A Debt/Equity ratio of 0.46 indicates that BSX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.46, BSX perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Altman-Z 4.28
ROIC/WACC0.84
WACC10.34%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 1.62 indicates that BSX should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.62, BSX is in line with its industry, outperforming 51.61% of the companies in the same industry.
  • A Quick Ratio of 1.08 indicates that BSX should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.08, BSX perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.08
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BSX.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.51% over the past year.
  • BSX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 26.01% yearly.
  • Looking at the last year, BSX shows a quite strong growth in Revenue. The Revenue has grown by 19.88% in the last year.
  • Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 15.16% on average per year.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.13% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 10.46% on average over the next years. This is quite good.
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue Next Year10.92%
Revenue Next 2Y10.66%
Revenue Next 3Y10.49%
Revenue Next 5Y10.46%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. BSX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 22.80, which indicates a rather expensive current valuation of BSX.
  • BSX's Price/Earnings ratio is a bit cheaper when compared to the industry. BSX is cheaper than 62.90% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 24.88, BSX is valued at the same level.
  • With a Price/Forward Earnings ratio of 19.86, BSX is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. BSX is around the same levels.
Industry RankSector Rank
PE 22.8
Fwd PE 19.86
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20

4.2 Price Multiples

  • BSX's Enterprise Value to EBITDA ratio is in line with the industry average.
  • BSX's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 28.18
EV/EBITDA 21.35
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of BSX may justify a higher PE ratio.
  • A more expensive valuation may be justified as BSX's earnings are expected to grow with 13.32% in the coming years.
PEG (NY)1.56
PEG (5Y)0.88
EPS Next 2Y13.93%
EPS Next 3Y13.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSX.DE Dividend Analysis

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BSX.DE Fundamentals: All Metrics, Ratios and Statistics

BOSTON SCIENTIFIC CORP

FRA:BSX (3/27/2026, 7:00:00 PM)

60.2

-1.2 (-1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.17%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap89.33B
Revenue(TTM)20.07B
Net Income(TTM)2.90B
Analysts85.5
Price Target91.04 (51.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.84%
Min EPS beat(2)1.62%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)1.62%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)5.56%
EPS beat(12)12
Avg EPS beat(12)5.7%
EPS beat(16)15
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.88%
Max Revenue beat(2)0.96%
Revenue beat(4)3
Avg Revenue beat(4)0.87%
Min Revenue beat(4)-0.88%
Max Revenue beat(4)2.43%
Revenue beat(8)7
Avg Revenue beat(8)1.73%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.59%
PT rev (1m)-15.64%
PT rev (3m)-16.54%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)-0.35%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)-0.05%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-0.36%
Revenue NY rev (1m)-0.46%
Revenue NY rev (3m)-0.45%
Valuation
Industry RankSector Rank
PE 22.8
Fwd PE 19.86
P/S 5.13
P/FCF 28.18
P/OCF 22.73
P/B 4.25
P/tB N/A
EV/EBITDA 21.35
EPS(TTM)2.64
EY4.39%
EPS(NY)3.03
Fwd EY5.03%
FCF(TTM)2.14
FCFY3.55%
OCF(TTM)2.65
OCFY4.4%
SpS11.72
BVpS14.15
TBVpS-0.62
PEG (NY)1.56
PEG (5Y)0.88
Graham Number28.99
Profitability
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROCE 10.46%
ROIC 8.7%
ROICexc 9.17%
ROICexgc 30.32%
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
FCFM 18.22%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
ROICexc(3y)7.95%
ROICexc(5y)7.36%
ROICexgc(3y)27.25%
ROICexgc(5y)24.65%
ROCE(3y)9.26%
ROCE(5y)8.51%
ROICexgc growth 3Y16.23%
ROICexgc growth 5Y30.87%
ROICexc growth 3Y13.89%
ROICexc growth 5Y25.4%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Debt/EBITDA 2.08
Cap/Depr 64.04%
Cap/Sales 4.36%
Interest Coverage 12.54
Cash Conversion 84.48%
Profit Quality 126.23%
Current Ratio 1.62
Quick Ratio 1.08
Altman-Z 4.28
F-Score7
WACC10.34%
ROIC/WACC0.84
Cap/Depr(3y)61.91%
Cap/Depr(5y)57.64%
Cap/Sales(3y)4.69%
Cap/Sales(5y)4.67%
Profit Quality(3y)127.68%
Profit Quality(5y)132.57%
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.92%
Revenue Next 2Y10.66%
Revenue Next 3Y10.49%
Revenue Next 5Y10.46%
EBIT growth 1Y30.81%
EBIT growth 3Y24.54%
EBIT growth 5Y34.7%
EBIT Next Year24.64%
EBIT Next 3Y16.7%
EBIT Next 5Y14.81%
FCF growth 1Y38.35%
FCF growth 3Y57.4%
FCF growth 5Y29.98%
OCF growth 1Y32.03%
OCF growth 3Y43.76%
OCF growth 5Y24.63%

BOSTON SCIENTIFIC CORP / BSX.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 4 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 8 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 22.8 and the Price/Book (PB) ratio is 4.25.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.65% in the next year.